128 related articles for article (PubMed ID: 30403945)
1. Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia.
Ebert BL; Krönke J
N Engl J Med; 2018 Nov; 379(19):1873-1874. PubMed ID: 30403945
[No Abstract] [Full Text] [Related]
2. Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models.
Minzel W; Venkatachalam A; Fink A; Hung E; Brachya G; Burstain I; Shaham M; Rivlin A; Omer I; Zinger A; Elias S; Winter E; Erdman PE; Sullivan RW; Fung L; Mercurio F; Li D; Vacca J; Kaushansky N; Shlush L; Oren M; Levine R; Pikarsky E; Snir-Alkalay I; Ben-Neriah Y
Cell; 2018 Sep; 175(1):171-185.e25. PubMed ID: 30146162
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract][Full Text] [Related]
4. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.
Järås M; Miller PG; Chu LP; Puram RV; Fink EC; Schneider RK; Al-Shahrour F; Peña P; Breyfogle LJ; Hartwell KA; McConkey ME; Cowley GS; Root DE; Kharas MG; Mullally A; Ebert BL
J Exp Med; 2014 Apr; 211(4):605-12. PubMed ID: 24616378
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
Fiskus W; Manshouri T; Birdwell C; Mill CP; Masarova L; Bose P; Kadia TM; Daver N; DiNardo CD; Borthakur G; Khoury JD; Verstovsek S; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):23. PubMed ID: 35102145
[No Abstract] [Full Text] [Related]
6. Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.
Shimamura T; Shibata J; Kurihara H; Mita T; Otsuki S; Sagara T; Hirai H; Iwasawa Y
Bioorg Med Chem Lett; 2006 Jul; 16(14):3751-4. PubMed ID: 16682184
[TBL] [Abstract][Full Text] [Related]
7. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.
Park SM; Miyamoto DK; Han GYQ; Chan M; Curnutt NM; Tran NL; Velleca A; Kim JH; Schurer A; Chang K; Xu W; Kharas MG; Woo CM
Cancer Cell; 2023 Apr; 41(4):726-739.e11. PubMed ID: 36898380
[TBL] [Abstract][Full Text] [Related]
8. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
9. Vinblastine sensitizes leukemia cells to cyclin-dependent kinase inhibitors, inducing acute cell cycle phase-independent apoptosis.
Bates DJ; Salerni BL; Lowrey CH; Eastman A
Cancer Biol Ther; 2011 Aug; 12(4):314-25. PubMed ID: 21768777
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models.
Wang L; Hu C; Wang A; Chen C; Wu J; Jiang Z; Zou F; Yu K; Wu H; Liu J; Wang W; Wang Z; Wang B; Qi Z; Liu Q; Wang W; Li L; Ge J; Liu J; Liu Q
Invest New Drugs; 2020 Oct; 38(5):1272-1281. PubMed ID: 31872348
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Tong WG; Chen R; Plunkett W; Siegel D; Sinha R; Harvey RD; Badros AZ; Popplewell L; Coutre S; Fox JA; Mahadocon K; Chen T; Kegley P; Hoch U; Wierda WG
J Clin Oncol; 2010 Jun; 28(18):3015-22. PubMed ID: 20479412
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combined CDK9/BET inhibition in preclinical models of MLL-rearranged acute leukemia.
McCalmont H; Li KL; Jones L; Toubia J; Bray SC; Casolari DA; Mayoh C; Samaraweera SE; Lewis ID; Prinjha RK; Smithers N; Wang S; Lock RB; D'Andrea RJ
Blood Adv; 2020 Jan; 4(2):296-300. PubMed ID: 31971998
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
16. Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo.
Cho SJ; Lee SS; Kim YJ; Park BD; Choi JS; Liu L; Ham YM; Moon Kim B; Lee SK
Cancer Lett; 2010 Jan; 287(2):196-206. PubMed ID: 19616371
[TBL] [Abstract][Full Text] [Related]
17. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
[TBL] [Abstract][Full Text] [Related]
18. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
19. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8.
Billot K; Coquil C; Villiers B; Josselin-Foll B; Desban N; Delehouzé C; Oumata N; Le Meur Y; Boletta A; Weimbs T; Grosch M; Witzgall R; Saunier S; Fischer E; Pontoglio M; Fautrel A; Mrug M; Wallace D; Tran PV; Trudel M; Bukanov N; Ibraghimov-Beskrovnaya O; Meijer L
Am J Physiol Renal Physiol; 2018 Jul; 315(1):F57-F73. PubMed ID: 29537311
[TBL] [Abstract][Full Text] [Related]
20. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia.
Beauchamp EM; Abedin SM; Radecki SG; Fischietti M; Arslan AD; Blyth GT; Yang A; Lantz C; Nelson A; Goo YA; Akpan I; Eklund EA; Frankfurt O; Fish EN; Thomas PM; Altman JK; Platanias LC
Blood; 2019 Mar; 133(11):1171-1185. PubMed ID: 30587525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
